SMITH & NEPHEW PLC
No SEC Form 4 filings for $SNN in the last 30 days.
The FTSE 100 fell 0.13% to 10,865.62 by 12:36 BST Wednesday, reversing part of an earlier rally. Investors weighed mixed earnings and hopes for a US-Iran-Oman interim deal to reopen the Strait of Hormuz for 60 days. Glencore, Next and Legal & General rose on updates, while Smith & Nephew fell after guidance cuts.
Smith & Nephew (SNN) reported Q2 2026 revenue of $1.6B, up 1.6% underlying and 2.8% reported, with FX adding 120 bps. U.S. revenue fell 1.3%, while emerging markets rose 10.6%. Half-year revenue was $3.1B. Trading profit rose $43M to $566M; gross margin was 71.1%.
FTSE 100 rose 0.2% to 10,879.38 and FTSE 250 gained 1.0% as oil fell on Middle East peace hopes. Brent Oct traded at $80.60/bbl vs $83.92. BP shares fell 4.9% despite Q2 underlying replacement profit of $10.31bn. Miners rose on higher metals; SpaceX shares slipped below IPO $135 after results expectations.
Over the past 7 days, alphai's AI scored 8 news stories mentioning SNN (SMITH & NEPHEW PLC). Coverage has skewed bearish: 0 bullish, 1 neutral, and 7 bearish.
Recent SNN coverage spans market movers, earnings and regulation.
Forecast cut is a negative fundamental catalyst, but the article presents it as an earlier-week move without new updates.
Guidance-related headwinds in China VBP and skin substitutes reimbursement changes are the key near-term earnings risk, partially offset by Sports Medicine strength and margin/cost savings.
Clear negative company-specific guidance cut tied to a revenue miss, likely to pressure estimates and sentiment.
Forecast cut is a direct negative fundamental catalyst for the stock.
Forecast cut is a direct fundamental negative, likely pressuring estimates and sentiment across medtech peers tied to joint replacement.
alphai scores every news story that mentions SNN with an AI model for sentiment and relevance, and aggregates insider trades from SMITH & NEPHEW PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
The FTSE 100 fell 0.13% to 10,865.62 by 12:36 BST Wednesday, reversing part of an earlier rally. Investors weighed mixed earnings and hopes for a US-Iran-Oman interim deal to reopen the Strait of Hormuz for 60 days. Glencore, Next and Legal & General rose on updates, while Smith & Nephew fell after guidance cuts.
6 min readSmith & Nephew (SNN) reported Q2 2026 revenue of $1.6B, up 1.6% underlying and 2.8% reported, with FX adding 120 bps. U.S. revenue fell 1.3%, while emerging markets rose 10.6%. Half-year revenue was $3.1B. Trading profit rose $43M to $566M; gross margin was 71.1%.
6 min readFTSE 100 rose 0.2% to 10,879.38 and FTSE 250 gained 1.0% as oil fell on Middle East peace hopes. Brent Oct traded at $80.60/bbl vs $83.92. BP shares fell 4.9% despite Q2 underlying replacement profit of $10.31bn. Miners rose on higher metals; SpaceX shares slipped below IPO $135 after results expectations.
7 min readThe UK FTSE 100 rose modestly in Tuesday morning trading, reaching 10,893.30, up 35.63 points or 0.33%. Mining shares led gains, including Antofagasta (+4.5%) and Glencore (+4%), plus Anglo American, Rio Tinto and Endeavour Mining. BP rose after more than doubling its Q2 replacement cost profit. HSBC fell 1.7% despite better-than-expected Q2 results and a higher cost-savings target.
4 min readEuropean shares mostly rose after positive company earnings and upbeat US manufacturing data. The STOXX 600 added 0.4% to 654.75. Movers included Travis Perkins up ~16%, Keller Group down 1.3%, Smith & Nephew down 6.7% on a weaker US demand outlook, and Lufthansa down 10% on lower operating profit guidance.
6 min readLondon’s FTSE 100 opened higher, up about 30 points to around 10,888, with miners and defence stocks offsetting weakness in HSBC. HSBC reported profit growth and resumed buybacks, though analysts said the buyback was smaller than expected. Travis Perkins shares rose after interim results. Smith+Nephew cut full-year revenue growth guidance; BP reported sharply higher Q2 profits.
7 min readSmith & Nephew shares fell about 5.9% to 1,126.5p after the company reported first-half 2026 results and cut its full-year underlying revenue growth forecast to about 4%–6% from ~6%. Q2 underlying revenue growth was 1.6% versus ~3.7% expected, citing weaker U.S. knee implant demand and temporary U.S. hip headwinds.
4 min readBritish stocks rose on Tuesday, with the FTSE 100 up 0.55% as markets reacted to signs of U.S.-Iran diplomacy. The rally followed U.S. comments on Strait of Hormuz talks and amid disputes over a Gaza transition framework involving Donald Trump and Benjamin Netanyahu. Company updates included BP profit and dividend increases, HSBC guidance lift and buyback, and Segro’s £14.3bn takeover by Prologis.
7 min readSmith+Nephew said the FDA granted De Novo classification for its TESSA Spatial Surgery System, an intra-articular orthopedic stereotaxic navigation device for ACL reconstruction. The system uses pre-op MR/CT scans and cloud AI on AWS, overlaid on live 4K arthroscopic video. Commercial launch is planned for Q3 2026, with broader deployment in 2027.
4 min readRomanian state nuclear firm Nuclearelectrica (BVB: SNN) said it is responding to a prime minister control body report criticizing its SMR Doicesti partnership with Nova Power & Gas (NPG). Nuclearelectrica disputed NPG’s EUR 20m improvement-payment claim, cited feasibility-study financing terms, and said site selection complied with law. The control body cited 20 months delay and USD 3.8bn cost increases.
6 min read
